Marian Benroubi

1.2k total citations
17 papers, 603 citations indexed

About

Marian Benroubi is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Genetics. According to data from OpenAlex, Marian Benroubi has authored 17 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Marian Benroubi's work include Diabetes Management and Research (14 papers), Diabetes Treatment and Management (13 papers) and Diabetes and associated disorders (4 papers). Marian Benroubi is often cited by papers focused on Diabetes Management and Research (14 papers), Diabetes Treatment and Management (13 papers) and Diabetes and associated disorders (4 papers). Marian Benroubi collaborates with scholars based in Greece, Italy and France. Marian Benroubi's co-authors include Jui‐Hung Sun, Francesco Giorgino, V. Pechtner, Alan G. Zimmermann, Ryuzo Kawamori, Vito Borzı̀, P. Valensi, Wenying Yang, М. В. Шестакова and Janusz Gumprecht and has published in prestigious journals such as Diabetes Care, The Journal of Physiology and Patient Education and Counseling.

In The Last Decade

Marian Benroubi

16 papers receiving 572 citations

Peers

Countries citing papers authored by Marian Benroubi

Since Specialization

Citations

This map shows the geographic impact of Marian Benroubi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marian Benroubi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marian Benroubi more than expected).

Fields of papers citing papers by Marian Benroubi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marian Benroubi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marian Benroubi. The network helps show where Marian Benroubi may publish in the future.

Co-authorship network of co-authors of Marian Benroubi

This figure shows the co-authorship network connecting the top 25 collaborators of Marian Benroubi. A scholar is included among the top collaborators of Marian Benroubi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marian Benroubi. Marian Benroubi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) 2015 ·Diabetes Care ·Francesco Giorgino, Marian Benroubi, Jui‐Hung Sun, Alan G. Zimmermann, V. Pechtner	205
2	Efficacy and Safety of Once Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Patients (AWARD-2) 2014 ·Canadian Journal of Diabetes ·Francesco Giorgino, Marian Benroubi, Jui‐Hung Sun, Alan G. Zimmermann, V. Pechtner	13
3	Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study 2013 ·Current Medical Research and Opinion ·Aytekin Oğuz, Marian Benroubi, Kerstin Brismar, (unknown), (unknown), Simon Cleall, Joseph M. Giaconia, (unknown)	25
4	Predictors of achieving HbA_1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study 2013 ·Current Medical Research and Opinion ·P. Valensi, (unknown), Marian Benroubi, Ryuzo Kawamori, Vito Borzı̀, Siddharth Shah, Yang Wen-ying, (unknown), Jes B. Hansen, Janusz Gumprecht, (unknown)	8
5	Predictors of postprandial blood glucose response to biphasic insulin analogue therapy 2012 ·Primary care diabetes ·Vito Borzı̀, Marian Benroubi, Janusz Gumprecht, Ryuzo Kawamori, Robert J. Ligthelm, (unknown), Siddharth Shah, М. В. Шестакова, Yang Wen-ying, P. Valensi	1
6	Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE 2012 ·Diabetes Therapy ·Andreas Liebl, Steven M. Jones, Albert Goday, Marian Benroubi, Conxa Castell, Axel Haupt, Claudia Nicolay, Helen T. Smith	12
7	Fear, guilt feelings and misconceptions: Barriers to effective insulin treatment in type 2 diabetes 2011 ·Diabetes Research and Clinical Practice ·Marian Benroubi	34
8	Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries 2011 ·Current Medical Research and Opinion ·Andreas Liebl, Stephen C. Jones, Marian Benroubi, Conxa Castell, Albert Goday, Marie‐Aline Charles, Helen T. Smith, Claudia Nicolay, Alexander I. F. Simpson	31
9	Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study* 2009 ·Current Medical Research and Opinion ·Stephen C. Jones, Marian Benroubi, Conxa Castell, Albert Goday, Andreas Liebl, (unknown), Claudia Nicolay, Alexander I. F. Simpson, Aodán Tynan	44
10	Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix^®30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE^™observational study 2009 ·International Journal of Clinical Practice ·Janusz Gumprecht, Marian Benroubi, Vito Borzı̀, Ryuzo Kawamori, (unknown), (unknown), М. В. Шестакова, Wenying Yang, Robert J. Ligthelm, P. Valensi, (unknown)	39
11	Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix^®30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study 2009 ·International Journal of Clinical Practice ·P. Valensi, Marian Benroubi, Vito Borzı̀, Jakub Gumprecht, Ryuzo Kawamori, (unknown), (unknown), М. В. Шестакова, Wenying Yang, (unknown)	61
12	Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix^®30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study 2009 ·International Journal of Clinical Practice ·(unknown), Marian Benroubi, Vito Borzı̀, Jakub Gumprecht, Ryuzo Kawamori, (unknown), М. В. Шестакова, Wenying Yang, P. Valensi, (unknown)	36
13	Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study 2009 ·Current Medical Research and Opinion ·Wenying Yang, Marian Benroubi, Vito Borzı̀, Janusz Gumprecht, Ryuzo Kawamori, (unknown), Siddharth Shah, М. В. Шестакова, Robert J. Ligthelm, Paul Valensi, (unknown)	11
14	The IMPROVE™ study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts 2008 ·International Journal of Clinical Practice ·P. Valensi, Marian Benroubi, Vito Borzı̀, Janusz Gumprecht, Ryuzo Kawamori, (unknown), (unknown), М. В. Шестакова, Wenying Yang, (unknown)	78
15	The patients' voice: testimonies from patients suffering from chronic disease 1995 ·Patient Education and Counseling ·Andrea Z. LaCroix, (unknown), (unknown), Marian Benroubi	1
16	Effect of the Long-Acting Somatostatin Analogue SMS 201-995 on the Glycaemic Control in Insulin-Treated Diabetics 1986 ·Scandinavian Journal of Gastroenterology ·B. Karamanos, G. Tolis, (unknown), (unknown), Marian Benroubi, (unknown), (unknown)	3
17	Naloxone increases blood flow in the human hand. 1985 ·The Journal of Physiology ·(unknown), Marian Benroubi, D A Pyke, Philip Wiles	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact